Science

Bisantrene is a small molecule anti-cancer drug which has potential as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. History of Bisantrene Bisantrene was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the anthracyclines. Lederle trialled Bisantrene on a wide range of cancers in the 1980s (more than 40 clinical trials) and it showed particular promise in leukemias, breast cancer and ovarian cancer. Bisantrene was studied in a large Phase III breast cancer trial in the late…

Latest News

+

Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special…

In >40 clinical trials, Bisantrene has been shown to have low cardiotoxicityThis study will assess the molecular mechanisms of Bisantrene…

Former Senior Vice President of Clinical Development at Syneos HealthDr Fuller brings over 30 years’ experience in oncology, international markets,…